Chad Thomas Campbell - 16 Jul 2025 Form 4 Insider Report for ANGIODYNAMICS INC (ANGO)

Role
SVP/GM, Vascular Access
Signature
/s/ Lawrence T. Weiss, Attorney in Fact
Issuer symbol
ANGO
Transactions as of
16 Jul 2025
Net transactions value
$0
Form type
4
Filing time
18 Jul 2025, 18:06:21 UTC
Previous filing
25 Jul 2024
Next filing
22 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Campbell Chad Thomas SVP/GM, Vascular Access 14 PLAZA DRIVE, LATHAM /s/ Lawrence T. Weiss, Attorney in Fact 18 Jul 2025 0001706852

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANGO Common Stock Award $0 +26,268 +39% $0.000000 94,076 16 Jul 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANGO Performance Right Award $0 +26,268 $0.000000 26,268 16 Jul 2025 Common Stock 26,268 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The acquisition of 26,268 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 26,268 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 16, 2026, such that 25% of the restricted stock units will vest on each of July 16, 2026, 2027, 2028 and 2029.
F2 Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

Remarks:

Exhibit 24.1 - Power of Attorney